Donovan Joanne M. 4

What Happened

• Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics (EWTX), exercised stock options and sold shares in early May 2026. On May 5 she exercised 50,000 option shares at $7.08 each (cost $354,000) and sold 50,000 shares in the open market for total proceeds reported as $1,928,400. Separately, on May 4 she sold 5,230 shares in the open market for $163,663. The filing also reports a related derivative disposition of 50,000 shares (reported at $0.00) tied to the option conversion/settlement.

Key Details

• Transaction dates: May 4, 2026 (sale of 5,230 shares); May 5, 2026 (exercise of 50,000 options and sale of 50,000 shares; derivative disposition of 50,000).
• Prices and values reported:
  • May 4 sale: 5,230 shares at an average $31.29 — proceeds $163,663 (sales ranged $30.72–$31.66). (F2)
  • May 5 exercise: 50,000 shares acquired at $7.08 — cost $354,000.
  • May 5 sale: 50,000 shares at an average $38.57 — proceeds $1,928,400 (sales ranged $38.00–$39.96). (F3)
  • Derivative disposition: 50,000 at $0.00 (reported as disposition of derivative interest).
• Total gross proceeds from the two reported sales ≈ $2,092,063; exercise cost reported $354,000. (Does not account for taxes, fees or share withholding.)
• Footnotes:
  • F1: The sales were effected under a Rule 10b5‑1 trading plan adopted Dec 26, 2025.
  • F4: The exercised options vest monthly (1/48th) beginning Sept 17, 2023, subject to continued service.
• Shares owned following the reported transactions: not specified in the information provided in this summary.
• Filing timeliness: Form 4 was filed May 5, 2026 for transactions dated May 4–5, 2026 (filed next day).

Context

• The filing shows an option exercise (code M) and same‑day sale of the resulting shares, which is a common pattern when insiders exercise stock options and sell shares immediately to cover exercise cost or to monetize gains. The May 4 sale was executed under a pre-established 10b5‑1 plan, which typically sets automated rules for timing and size of sales. This report is factual disclosure of transactions; it does not state the insider’s motives.